Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Clik1 Inhibitors

Clik1 inhibitors are chemical compounds that specifically target and inhibit the activity of Clik1, a kinase that is part of a family of proteins involved in cell signaling and regulation of cellular processes. Clik1, also referred to as CLIK1 (Cdc2-like kinase 1), plays a critical role in the regulation of cell cycle progression, particularly in controlling the transition between various phases of the cell cycle. Kinases like Clik1 are responsible for the phosphorylation of target proteins, which alters their function and contributes to the regulation of key cellular activities, such as division and replication. Clik1 inhibitors block the kinase activity by interfering with its ability to phosphorylate substrate proteins, thus impeding the downstream signaling pathways that rely on Clik1's enzymatic action.

The mechanism of action of Clik1 inhibitors often involves binding to the ATP-binding site of the kinase, which is essential for its enzymatic activity. By preventing ATP from binding, the inhibitors effectively stop Clik1 from transferring phosphate groups to its target proteins. Inhibition of Clik1 disrupts normal cell cycle regulation, providing valuable insights into the role of this kinase in coordinating cellular division and growth. Clik1's involvement in these processes makes it a key regulator of the complex machinery that governs cell cycle checkpoints. By studying Clik1 inhibitors, researchers can better understand the mechanisms of kinase regulation and how phosphorylation events control critical aspects of cell biology. These inhibitors offer a useful tool for exploring the broader functions of kinases in cellular signaling and the coordination of growth-related processes in various cell types.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

AS703026

1236699-92-5sc-364412
sc-364412A
5 mg
10 mg
$80.00
$130.00
(0)

AS-703026 inhibits CLK1 by blocking its ATP-binding site, thereby preventing phosphorylation of SR proteins. This disruption of splicing regulation contributes to its anti-tumor effects in cancer therapy.

CX-4945

1009820-21-6sc-364475
sc-364475A
2 mg
50 mg
$183.00
$800.00
9
(2)

CX-4945 inhibits CLK1 by binding to its ATP-binding site. It disrupts the phosphorylation of SR proteins and modulates alternative splicing, making it a potential therapeutic agent for various diseases, including cancer.

DCC-2036

1020172-07-9sc-364482
sc-364482A
10 mg
50 mg
$480.00
$1455.00
(0)

DCC-2036 is a small molecule inhibitor of CLK1 that competes with ATP for binding to the kinase domain. By inhibiting CLK1 activity, it disrupts the splicing machinery and modulates alternative splicing events in cells.